If you weren’t already aware, the era of emerging biotechs has arrived.

Last year, these companies accounted for 72% of 2,853 late-stage drugs in the collective industry pipeline, up from 65% of 2,083 medicines in 2013. Meanwhile, 47% of the therapies launched in the U.S. in 2018 were attributed to emerging biotechs, which were defined as spending less than $200 million annually on R&D and having less than $500 million in revenue.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy